Though the titers of plasma IgA and IgG antibodies against SARS-CoV-2 spike and RBD in severe patients showed similar or even higher level compared with mild COVID-19 patients during early infection (Supplementary Fig. 10a, b), the plasma neutralization potency (calculated as IC100 divided by antibody titers) in severe patients was significantly lower than mild and moderate patients (Fig. 5j). The gene discussed is CD79A; the disease is infection.